Sanofi Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Sanofi heeft een totaal eigen vermogen van €73.0B en een totale schuld van €23.8B, wat de schuld-eigenvermogensverhouding op 32.5% brengt. De totale activa en totale passiva bedragen respectievelijk €129.8B en €56.8B. De EBIT Sanofi is €9.0B waardoor de rentedekking 56.4 is. Het heeft contanten en kortetermijnbeleggingen van €6.8B.

Belangrijke informatie

32.5%

Verhouding schuld/eigen vermogen

€23.75b

Schuld

Rente dekkingsratio	56.4x
Contant	€6.80b
Aandelen	€73.00b
Totaal verplichtingen	€56.76b
Totaal activa	€129.76b

Recente financiële gezondheidsupdates

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Aug 17

Recent updates

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sep 10

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Aug 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €30.1B ) SAN } overtreffen de korte termijn passiva ( €30.0B ).

Langlopende schulden: De kortetermijnactiva SAN ( €30.1B ) overtreffen de langetermijnschulden ( €26.7B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 23.2% ) SAN wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van SAN is de afgelopen 5 jaar gedaald van 47.2% naar 32.5%.

Schuldendekking: De schuld van SAN wordt goed gedekt door de operationele kasstroom ( 34.2% ).

Rentedekking: De rentebetalingen op de schuld van SAN worden goed gedekt door EBIT ( 56.4 x dekking).

Sanofi Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Recent updates

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven